Updated time: 2023-10-31 10:33:27
12A-1040125
CN ZL2016 8 0023106.0
The invention is based on the unexpected discoveries of the critical time point for cardiomyocyte reprogramming and a gene set, including FoxM1, Id1, and JNK3, that plays important roles in cardiomyocyte proliferation. Thus, enhancers or inhibitors of the genes could be used to promote cardiomyocyte proliferation in heart damages. In particular, a combination of FoxM1 enhancer, an Id1 enhancer, and a JNK3 inhibitor could be used for this purpose.
The invention to determine the critical time point for cardiomyocyte proliferation based on the reprogramming technique is one of the advantages of the invention. The selected cocktail composed of FoxM1, Id1, and Jnk3-shRNA in the invention disclosure was first provided to significantly increase cardiomyocyte proliferation supporting heart function after injury. The cocktail is first studied together for their potential of heart therapy is the other advantage for this invention.
Heart regeneration has been a long-standing challenge due to the low proliferative ability of mammalian adult cardiomyocytes. Cardiomyocytes execute their final round of DNA synthesis and karyokinesis, become binucleated, and subsequently exit the cell cycle during the first week after birth. Although the remnants cardiomyocytes possess certain degree of proliferation after a cardiac damage, the efficiency is low. In the present invention, a combination of active agents selected from a FoxM1 enhancer, an Id1 enhancer, and a JNK3 inhibitor and the uses thereof in promoting cardiomyocyte proliferation and treating heart diseases.
Patrick CH Hsieh, Yuan-Yuan Cheng
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

A therapeutic gene cocktail for heart regeneration